On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion.
Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am posting the observation and holding the interpretation back.
Numbers, method and the conditions under which they were collected are below. Interpret them however they warrant.
Fair, and the limits you put on it are the part I will remember.
Signalling through cyclic AMP is the canonical pathway and is not the only one. Beta-arrestin recruitment differs between ligands and its clinical significance here is unestablished.
What I would check first on vagal afferents is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Half-life extension by albumin binding through a fatty acid chain trades free fraction for duration. It is an engineering solution with a cost, and the cost is that the bound fraction is not active.
The variance between people here is larger than the effect being discussed.
Post #6 is the version of this I will quote in future. One addition.
Reading this vagal afferents thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
On vagal afferents, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
|
+52 | 57 | 25k | just now |
|
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
|
+90 | 98 | 30k | 22h |
|
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…
|
+57 | 63 | 1k | 6mo |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
|
+73 | 78 | 3.5k | 2mo |
|
Revisiting: GLP-1 receptor distribution: central and peripheral
Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
|
+61 | 66 | 15k | 8mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Books and papers worth reading that are not about this at all
On the subject in the title: Books and papers worth reading that are not about this at all Working notes rather than a conclusion. Reading back through what has been written here about books and papers, three…
|
+13 | 17 | 13k | 19mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. Reading back through what has been written here about…
|
+4 | 8 | 14k | 8mo |
|
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I…
|
+115 | 130 | 44k | 13mo |
|
Does dual agonism explain the effect size, or is it dose?
Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…
|
+62 | 68 | 2.6k | 29d |
|
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
|
4 | 42k | 11mo |